Biotechnology - Licensing

Filter

Current filters:

Licensing

Popular Filters

1 to 25 of 395 results

3SBio gains exclusive license for PharmAbcine’s tanibirumab

20-11-2014

Chinese biotech firm 3SBio Inc has entered into an exclusive license with PharmAbcine for the development,…

3SBioBiotechnologyBrazilChinaLicensingOncologyPharmAbcineRussiatanibirumabThailand

Dicerna licenses rights to Tekmira technology

Dicerna licenses rights to Tekmira technology

18-11-2014

US RNAi therapeutics specialist Dicerna Pharmaceuticals has entered a licensing agreement for to use…

BiotechnologyDCR-PH1Dicerna PharmaceuticalsLicensingRare diseasesTekmira PharmaceuticalsUSA

Merck enters lucrative cancer alliance with Pfizer

Merck enters lucrative cancer alliance with Pfizer

17-11-2014

Germany’s Merck KGaA said today that it has entered into a global agreement with US pharma giant Pfizer…

BiotechnologyGermanyLicensingMarkets & MarketingMerck KGaAMerck SeronoMSB0010718COncologyPfizerUSAXalkori

Onxeo receives $25M milestone payment from Spectrum on Beleodaq

14-11-2014

Onxeo, created by a merger between French company BioAlliance Pharma, and Danish biopharmaceutical company…

BeleodaqBiotechnologyFinancialHematologyLicensingOncologyOnxeoSpectrum PharmaceuticalsUSA

Geron in up to $935 million deal with Janssen for imetelstat

Geron in up to $935 million deal with Janssen for imetelstat

14-11-2014

Geron Corp has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech,…

BiotechnologyGeron CorpGlobalHematologyimetelstatJanssen BiotechJohnson & JohnsonLicensingOncology

Boehringer Ingelheim drops option for Athera’s PC-MAb

12-11-2014

Sweden’s Athera Biotechnologies, which is 65% owned by Karolinska Development, says that German family-owned…

Athera BiotechnologiesBiotechnologyBoehringer IngelheimCardio-vascularLicensing

Servier gains ex-US/Japan rights to Intarcia diabetes product ITCA 650

Servier gains ex-US/Japan rights to Intarcia diabetes product ITCA 650

12-11-2014

USA-based biotech firm Intarcia Therapeutics has started a strategic partnership with French independent…

BiotechnologyDiabetesexenatide pumpFranceIntarcia TherapeuticsITCA 650LicensingServier

AVEO inks deal with Ophthotech for tivozanib in ocular diseases

AVEO inks deal with Ophthotech for tivozanib in ocular diseases

11-11-2014

US biotech firm AVEO Oncology has entered into a research and exclusive option agreement with Ophthotech…

AVEO OncologyBiotechnologyLicensingOphthalmicsOphthotechtivozanibUSA

Xencor regains rights to XmAb5871 from Amgen

29-10-2014

US drug developer Xencor revealed yesterday that it has regained all development and commercial rights…

AmgenAnti-Arthritics/RheumaticsBiotechnologyImmunologicalsLicensingResearchXencorXmAb5871

Ferrer buys $8 million of Alexza shares, to eliminate certain Adasuve milestone payments

Ferrer buys $8 million of Alexza shares, to eliminate certain Adasuve milestone payments

28-10-2014

US drugmaker Alexza Pharmaceuticals and privately-held Spanish firm Grupo Ferrer Internacional have amended…

AdasuveAlexza PharmaceuticalBiotechnologyFerrer InternacionalFinancialLicensingNeurologicalUSA

Licensing deal index shows re-emergence of late-stage deals

Licensing deal index shows re-emergence of late-stage deals

28-10-2014

Licensing deals among biotech companies have recently shown a healthy surge, especially in later stages.

BiotechnologyCelgene Corp.FinancialLicensingMorrisonUK

Takeda licenses commercial rights to Mersana Fleximer-ADC

27-10-2014

Just seven months after the collaboration was announced, Japan’s largest drugmaker Takeda Pharmaceutical…

BiotechnologyFleximerLicensingMersana TherapeuticsMillennium PharmaceuticalsOncologyTakeda Pharmaceutical

GSK expands collaboration with Five Prime Therapeutics

GSK expands collaboration with Five Prime Therapeutics

27-10-2014

US biotech firm Five Prime Therapeutics is expanding its respiratory disease research collaboration with…

BiotechnologyFive Prime TherapeuticsGlaxoSmithKlineLicensingResearchRespiratory and Pulmonary

CTI acquires tosedostat rights from Vernalis and Chroma

CTI acquires tosedostat rights from Vernalis and Chroma

27-10-2014

Blood-related cancer specialist CTI BioPharma has acquired the worldwide rights to tosedostat through…

BiotechnologyChroma TherapeuticsCTI BioPharmaLicensingOncologytosedostatUSAVernalis

WuXi PharmaTech collaborates on genomic profiling for China

24-10-2014

China’s WuXi PharmaTech has entered into a collaboration with USA-based Foundation Medicine to offer…

BiotechnologyChinaFoundation MedicineLicensingOncologyWuXi PharmaTech

Sutro Biopharma and Celgene expand accord; add buyout option

23-10-2014

Sutro Biopharma today announced it has entered into a strategic collaboration and option agreement with…

BiotechnologyCelgene Corp.LicensingMergers & AcquisitionsOncologySutro Biopharma

PhosImmune and PureMHC to collaborate on antibody-based immunotherapies for cancer

PhosImmune and PureMHC to collaborate on antibody-based immunotherapies for cancer

22-10-2014

Clinical-stage oncology biotech company PhosImmune has entered into a license and collaboration agreement…

BiotechnologyLicensingOncologyPhosImmunePureMHCUSA

NewLink Genetics out-licenses NLG919 to Genentech

NewLink Genetics out-licenses NLG919 to Genentech

20-10-2014

US biotech firm NewLink Genetics saw its share price rocket 21.2% in morning trading today, after it…

BiotechnologyGenentechGlobalLicensingNewLink GeneticsNLG919OncologyRoche

Astellas and CoMentis to end Alzheimer’s collaboration

20-10-2014

Japanese drug major Astellas Pharma and US biotech firm CoMentis have said they will end their worldwide…

Astellas PharmaBiotechnologyCoMentisLicensingNeurologicalResearch

Aduro expands deal with Janssen to lung cancer; worth up to $817 million

Aduro expands deal with Janssen to lung cancer; worth up to $817 million

17-10-2014

Privately-held US cancer immunotherapy developer Aduro BioTech has entered into its second agreement…

Aduro BioTechBiotechnologyGlobalJanssen BiotechJohnson & JohnsonLicensingOncologyResearch

Auspherix and Domainex collaborate for new drugs to combat antibiotic-resistance

Auspherix and Domainex collaborate for new drugs to combat antibiotic-resistance

15-10-2014

UK biotech firm Domainex and Australian drug discovery company Auspherix, a spin-out from the University…

AuspherixAuspherix PtyAustraliaBiotechnologyDomainexHealthLicensingPharmaceutical sciencesPharmacologyResearchUK

Imaxio signs option for a license agreement with DKFZ

14-10-2014

French vaccine focussed biotech firm Imaxio has signed an option for a license agreement with the German…

Anti-viralsBiotechnologyImaxioLicensingResearch

After nine years, AstraZeneca finally ditches Targacept

12-10-2014

On October 8, 2014, Anglo-Swedish pharma major AstraZeneca finally terminated its collaborative research…

AstraZenecaBiotechnologyGenito-urinaryLicensingNeurologicalTargacept

Roche acquires exclusive rights to AbVitro's extension-based target enrichment technology

Roche acquires exclusive rights to AbVitro's extension-based target enrichment technology

09-10-2014

Swiss drug major Roche has acquired exclusive rights to a primer extension-based target enrichment technology…

AbVitroBiotechnologyLicensingRocheSwitzerland

1 to 25 of 395 results

Back to top